Deprecated: Creation of dynamic property cls_session::$session_data_table is deprecated in /www/sites/www.188bio.com/index/systems/cls_session.php on line 49
LKT/SAR245409/S0269/1 mg188bio精品生物—专注于实验室精品爆款的电商平台 - 蚂蚁淘旗下精选188款生物医学科研用品
您好,欢迎您进入188进口试剂采购网网站! 服务热线:4000-520-616
蚂蚁淘商城 | 现货促销 | 科研狗 | 生物在线
产品资料

LKT/SAR245409/S0269/1 mg

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References

Description

SAR245409 is a pyridopyrimidinone derivative that inhibits PI3K and mTOR. This compound exhibits anticancer chemotherapeutic activity and shows benefit in clinical trials as a potential treatment for advanced solid tumors. SAR245409 inhibits cell proliferation and tumor growth in a variety of cancer models.

Product Info

Cas No.

1349796-36-6

Purity

≥96%

Formula

C31H29N5O6S

Formula Wt.

599.66

IUPAC Name

N-[4-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-3-methoxy-4-methylbenzamide

Synonym

XL765, Voxtalisib, SAR245409

Appearance

Off white to light yellow powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

Info Sheet

S0269 Info Sheet PDF

References

Yu P, Laird AD, Du X, et al. Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Impacting the PI3K Pathway. Mol Cancer Ther. 2014 Mar 19. [Epub ahead of print]. PMID: 24634413.

Papadopoulos K, Tabernero J, Markman B, et al. Phase I safety, pharmacokinetic and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Clin Cancer Res. 2014 Feb 28. [Epub ahead of print]. PMID: 24583798.

新闻动态
行业前沿
技术文章
最新产品